So they initially planned to begin their marketing in June and they moved it to July, the product launch in September, then late September, it's now at the beginning of August and the marketing launch hasn't commenced, although they assure us that it's imminent. You've obviously referenced the couple animals studies that came out, as well as smoothed onto the NIH lab there. If you have not reviewed this information both are available within the Investor Relations section of ChromaDex's website at www.chromadex.com.I would now like to turn the conference call over to Brianna Gerber, Vice President of FP&A and Investor Relations. On a sequential basis, our total operating expenses for the second quarter of 2020 was $12.8 million, down $1.4 million, compared to the first quarter of 2020. We're a responsible company that spends money and follows the rules that the FDA has laid out. But they're thinking long-term and they're thinking in a significant way and they have many facets of their organization working on it and we think they're -- they've got a good idea for how they want to pursue it. This approach follows their successful rollout of TRU NIAGEN in New Zealand, a small but steadily growing market for us. And that's just the way we're going about doing it quarter-by-quarter, year-by-year. We expect it to increase in the third quarter due to the litigation in Delaware and the litigation in New York.And then by the end of next year, do you believe that, that goes away? Excluding legal fees, severance, restructuring and equity compensation expense, second quarter 2020 G&A expense was lower by $0.6 million versus first quarter 2020 comparable G&A expense. And a lot of the collaborative studies that have started in studies like this have transitioned from successful preclinical studies, mouse model type studies into human clinical trials.

This is a logical next step to assess whether increasing NAD levels within our supplementation benefits the innate immune response in a COVID-19 model of mice and hamsters. We believe TRU NIAGEN is positioned for strong growth in Australia in 2020 and beyond.Nestle Health Science has shared with us that they plan to begin the marketing efforts to educate consumers on the importance of cellular nutrition very soon. We continue to monitor daily e-commerce metrics, such as consumer acquisition cost to adjust messaging and spending, which is increasingly important in this fluid environment. Year-over-year, we delivered $2.6 million improvement in the second quarter of 2020 versus $2.1 million loss in the second quarter of 2019. We have seen Elysium's initial claim construction arguments and remain as confident as ever in the strength of our licensed patents. Quick Links And we're seeing strength, we're seeing significant rebounding here and so we're seeing growth, that's one reason. ChromaDex Corporation ... Robert Fried-- Chief Executive Officer. This included initial shipments of TRU NIAGEN beauty, sales in the base business excluding TRU NIAGEN beauty were roughly flat sequentially. The underlying business is measured by adjusted EBITDA, excluding total legal expense, achieved breakeven with the second quarter profit of $525,000. It depends on when these studies are completed and what the results say.Okay. Please go ahead.Yes. Speaking of marketing, the market is going to be up $3 million to $5 million for the year, it was up $1 million in the first half, so that suggests an acceleration in the second half. So it could be a few months, it's theoretically possible that it could be weeks, it's not likely, but it's theoretically possible. We take great pride in the fact that we are a fundamentally sound operation and conservative in the way we approach our business. And I guess what other studies are you watching most closely that are currently ongoing?Yes, I'll begin the answer to that and then I'll pass it over to Frank to contribute as well. Motley Fool Transcribers We expect continued improvement in selling and marketing expenses as a percentage of net sales, driven by strong sales from returning customers and scale on our business.Lastly, we continue to expect that G&A excluding severance and restructuring expenses and legal expense will be up by $1 million to $2 million year-over-year comparable to 2019 G&A expense excluding the Elysium-related bad debt expense in 2019. In addition, we introduced TRU NIAGEN beauty through cross-border sales in China as another test launch.E-commerce net sales were $8.1 million, a 24% increase year-over-year and slightly below first quarter. The webcast will be available at the Investor Relations section of our website at www.chromadex.com.With that it's now my pleasure to turn the call over to our Chief Executive Officer, Rob Fried. And then I think with regard to our savings programs, we have also highlighted that we expect about $2 million of savings based upon what we've implemented already and most of that would show up in 2021.Your next question comes from Raghuram Selvaraju with H.C. Wainwright. While there was not an immediate need for additional capital, we believe it was prudent given the economic uncertainty. They actually purchase wholesale bottles from ChromaDex and then resell it to their patients. There are a lot of companies that don't do that. As Chief Executive Officer and Director at ChromaDex Corp., Robert Fried made $5,160,444 in total compensation.